期刊
JOURNAL OF BIOLOGICAL CHEMISTRY
卷 286, 期 7, 页码 5100-5107出版社
AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
DOI: 10.1074/jbc.M110.172254
关键词
-
资金
- Wellcome Trust [083313]
- Deutsche Forschungsgemeinschaft [MU3050/2-1]
The NF kappa B transcription factor is a key component of immune and inflammatory signaling as its activation induces the expression of antimicrobial reagents, chemokines, cytokines, and anti-apoptotic factors. Many pathogens encode effector proteins that target factors regulating NF kappa B activity and can provide novel insights on regulatory mechanisms. Given the link of NF kappa B dysfunction with inflammatory diseases and some cancers, these effectors have therapeutic potential. Here, screening enteropathogenic Escherichia coli proteins for those implicated in suppressing NF kappa B function revealed that eGFP-NleC, unlike eGFP, strongly inhibited basal and TNF alpha-induced NF kappa B reporter activity to prevent secretion of the chemokine, IL-8. Work involving NleC variants, chemical inhibitors, and immunoprecipitation studies support NleC being a zinc metalloprotease that degrades NF kappa B-I kappa B alpha complexes. The findings are consistent with features between residues 33-65 recruiting NF kappa B for proteasomal-independent degradation by a mechanism inhibited by metalloprotease inhibitors or disruption of a consensus zinc metalloprotease motif spanning NleC residues 183-187. This raises the prospect that mammalian cells, or other pathogens, employ a similar mechanism to modulate NF kappa B activity. Moreover, NleC represents a novel tool for validating NF kappa B as a therapeutic target and, indeed, as a possible therapeutic reagent.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据